Literature DB >> 12406098

Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3).

Mario Cazzola1, Laura Cremonesi, Maria Papaioannou, Nadia Soriani, Anna Kioumi, Anastasia Charalambidou, Rita Paroni, Katerina Romtsou, Sonia Levi, Maurizio Ferrari, Paolo Arosio, John Christakis.   

Abstract

Iron overload may predominantly involve parenchymal or reticuloendothelial cells, the prototype of parenchymal iron overload being HFE-related genetic haemochromatosis. We studied a family with autosomal dominant hyperferritinaemia in whom the proband showed selective iron accumulation in the Kupffer cells on liver biopsy. Analysis of L and H ferritin genes excluded mutations responsible for hereditary hyperferritinaemia/cataract syndrome or similar translational disorders. Sequence analysis of the ferroportin gene (SLC11A3) in four individuals with hyperferritinaemia singled out a three base pair deletion in a region that contains four TTG repeats. This mutation removes a TTG unit from 780 to 791, and predicts the loss of one of three sequential valine residues 160-162. Denaturing high performance liquid chromatography can be used for its detection. SLC11A3 polymorphism analysis indicates that this probably represents a recurrent mutation due to slippage mispairing. Affected individuals may show marginally low serum iron and transferrin saturation, and young women may have marginally low haemoglobin concentration levels. Serum ferritin levels are directly related to age, but are 10-20 times higher than normal. Heterozygosity for the ferroportin Val 162 deletion represents the prototype of selective reticuloendothelial iron overload, and should be taken into account in the differential diagnosis of hereditary or congenital hyperferritinaemias.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406098     DOI: 10.1046/j.1365-2141.2002.03946.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  Identification of ferroportin disease in the Indian subcontinent.

Authors:  D F Wallace; P Browett; P Wong; H Kua; R Ameratunga; V N Subramaniam
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

2.  Ferroportin disease due to the A77D mutation in Australia.

Authors:  V N Subramaniam; D F Wallace; J L Dixon; L M Fletcher; D H Crawford
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

3.  Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress.

Authors:  De-Liang Zhang; Manik C Ghosh; Hayden Ollivierre; Yan Li; Tracey A Rouault
Journal:  Blood       Date:  2018-09-13       Impact factor: 22.113

4.  The molecular basis of ferroportin-linked hemochromatosis.

Authors:  Ivana De Domenico; Diane McVey Ward; Elizabeta Nemeth; Michael B Vaughn; Giovanni Musci; Tomas Ganz; Jerry Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-13       Impact factor: 11.205

5.  Wild-type and mutant ferroportins do not form oligomers in transfected cells.

Authors:  Ana Sofia Gonçalves; Françoise Muzeau; Rand Blaybel; Gilles Hetet; Fathi Driss; Constance Delaby; François Canonne-Hergaux; Carole Beaumont
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

Review 6.  The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1).

Authors:  Andrew T McKie; David J Barlow
Journal:  Pflugers Arch       Date:  2003-06-27       Impact factor: 3.657

7.  Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload.

Authors:  Monique G Zaahl; Alison T Merryweather-Clarke; Maritha J Kotze; Schalk van der Merwe; Louise Warnich; Kathryn J H Robson
Journal:  Hum Genet       Date:  2004-08-24       Impact factor: 4.132

8.  A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient.

Authors:  K E Arden; D F Wallace; J L Dixon; L Summerville; J W Searle; G J Anderson; G A Ramm; L W Powell; V N Subramaniam
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

Review 9.  Non-HFE haemochromatosis.

Authors:  Daniel-F Wallace; V-Nathan Subramaniam
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

Review 10.  Recent advances in understanding haemochromatosis: a transition state.

Authors:  K J H Robson; A T Merryweather-Clarke; E Cadet; V Viprakasit; M G Zaahl; J J Pointon; D J Weatherall; J Rochette
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.